<DOC>
	<DOCNO>NCT02117505</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability ( extent drug substance become available body ) JNJ-54781532 formulation 2 ( test ) compare JNJ-54781532 formulation 1 ( reference ) healthy participant fed condition single dose 150 milligram ( mg ) .</brief_summary>
	<brief_title>A Crossover Study Evaluate Relative Bioavailability Two JNJ-54781532 Tablet Formulations Healthy Adult Participants</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , open-label ( people know identity intervention ) , 2-treatment , 2-period , 2-sequence crossover ( participant may receive different intervention sequentially trial ) , single-center study JNJ-54781532 . The duration study approximately 5 week per participant . The study consist 3 part : Screening ( , 21 day study commences Day 1 ) ; Open-label Treatment ( consist 2 single-dose treatment , either JNJ-54781532 formulation 1 [ reference ] JNJ-54781532 formulation 2 [ test ] ) , subsequent 2-treatment period , separate washout period 7 day ) ; End-of-Study ( do upon completion 72-hour pharmacokinetic sample Day 4 Period 2 , time early withdrawal ) . All eligible participant randomly assign 1 2 treatment sequence ensure receive follow treatment , one period . Followed overnight fast least 10 hour participant administer study treatment 30 minute high-fat , high-calorie breakfast . Participants allow food 4 hour drug administration . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Relative bioavailability two formulation JNJ-54781532 ( test reference ) evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Female participant must either : 1 ) childbearing potential : postmenopausal surgically sterile screen 2 ) childbearing potential : Must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screening , agree use highly effective contraception throughout study period , 90 day final study drug administration . Women , heterosexually active Screening , must agree utilize highlyeffective method birth control become heterosexually active participation study Must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screening ; negative urine pregnancy test Day ( ) 1 Period 1 Female participant must agree donate ovum start screen throughout study period , 90 day final study drug administration If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate Investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 90 day receive last dose study drug Participants eligible accord follow tuberculosis ( TB ) screen criterion : 1 ) follow tuberculosis ( TB ) screen criterion 2 ) sign symptom suggestive active TB upon medical history and/or physical examination 3 ) recent close contact person active TB 4 . Within 2 month prior first administration study agent , negative Tspot QuantiFERONTB Gold test result History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection Participant major gastrointestinal ( GI ) surgery Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center Day ( ) 1 Period 1 Participant aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) great equal ( &gt; = ) upper limit normal ( ULN ) History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 1 year Screening positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine benzodiazepine ) screen Day ( ) 1 Period 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Biological Availability</keyword>
	<keyword>JNJ-39220675</keyword>
	<keyword>Healthy</keyword>
	<keyword>Phase 1</keyword>
</DOC>